Fujian Cosunter Pharmaceutical Co., Ltd.

Symbol: 300436.SZ

SHZ

17.31

CNY

Market price today

  • -10.9515

    P/E Ratio

  • 0.0000

    PEG Ratio

  • 2.76B

    MRK Cap

  • 0.00%

    DIV Yield

Fujian Cosunter Pharmaceutical Co., Ltd. (300436-SZ) Financial Statements

On the chart you can see the default numbers in dynamics for Fujian Cosunter Pharmaceutical Co., Ltd. (300436.SZ). Companys revenue shows the average of 293.612 M which is 0.134 % gowth. The average gross profit for the whole period is 227.47 M which is 0.103 %. The average gross profit ratio is 0.794 %. The net income growth for the company last year performance is 2.652 % which equals -0.525 % % on average for the whole company history.,

Balance Sheet

Diving into the fiscal trajectory of Fujian Cosunter Pharmaceutical Co., Ltd., we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to 0. A look back at the past year reveals a total asset change of 0.033. In the realm of current assets, 300436.SZ clocks in at 394.3 in the reporting currency. A significant portion of these assets, precisely 238.976, is held in cash and short-term investments. This segment shows a change of -0.393% when juxtaposed with last year's data. Long-term investments of the company, while not its focus, stand at 204.519, if any, in the reporting currency. This indicates a difference of 90.687% from the last reporting period, reflecting the company's strategic shifts. The debt profile of the company shows a total long-term debt of 84.138 in the reporting currency. This figure signifies a year_over_year change of 0.663%. Shareholder value, as depicted by the total shareholder equity, is valued at 928.462 in the reporting currency. The year over year change in this aspect is -0.110%. A deeper dive into the company's financials reveals additional details. The net receivables are valued at 54.786, with an inventory valuation of 68.66, and goodwill valued at 58.97, if any. The total intangible assets, if present, are valued at 122.28. Account payables and short-term debt are 94.96 and 227.41, respectively. The total debt is 311.55, with a net debt of 72.57. Other current liabilities amount to 0.91, adding to the total liabilities of 539.22. Lastly, the referred stock is valued at 0, if it exists.

common:word.in-mln

USD
Growth
TTM202220212020201920182017201620152014201320122011

balance-sheet.row.cash-and-short-term-investments

1063.7239393.6136
93.7
85.9
408.1
414.9
393.4
75.7
71.4
53.4
38.7

balance-sheet.row.short-term-investments

-157.93-33.8-7.3-6.1
-1.7
-3.6
-2.6
-0.5
-0.7
0
0
0
0

balance-sheet.row.net-receivables

255.7254.862.756.1
65
72.8
38.7
25.9
13.6
25.8
20
5.2
8.8

balance-sheet.row.inventory

383.4168.781.852.7
35.4
39.2
24.3
17.6
13.2
9.7
12.9
7.6
4.4

balance-sheet.row.other-current-assets

165.5531.911.812.7
3.8
8.1
1.8
2.1
20.3
0
-0.5
0
-0.5

balance-sheet.row.total-current-assets

1868.38394.3549.9257.5
198
205.9
472.9
460.5
440.5
111.2
103.8
66.3
51.5

balance-sheet.row.property-plant-equipment-net

2478.48584.8509.6420.8
271.1
205.6
116.2
118.1
108
85.1
68.9
63.1
45.3

balance-sheet.row.goodwill

235.87595959
59
59
0
0
0
0
0
0
0

balance-sheet.row.intangible-assets

808.5122.3144.2150
182.2
140.1
61.5
48.6
42.4
24
22.2
17.8
10.2

balance-sheet.row.goodwill-and-intangible-assets

1044.38181.3203.2208.9
241.2
199.1
61.5
48.6
42.4
24
22.2
17.8
10.2

balance-sheet.row.long-term-investments

805.67204.5107.376.1
41.5
18.1
20.8
16.8
5.7
0
0
0
0

balance-sheet.row.tax-assets

255.8571.143.123.9
16.8
13.8
8
5
3
2.7
2.6
2.1
2.1

balance-sheet.row.other-non-current-assets

198.0858.933.718.6
127.3
212
57.1
51.7
1.3
1.1
0.1
0.2
0.3

balance-sheet.row.total-non-current-assets

4782.461100.5896.9748.2
697.9
648.6
263.6
240.1
160.2
112.9
93.7
83.1
57.8

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

6650.841494.81446.81005.8
895.9
854.5
736.5
700.7
600.7
224.1
197.5
149.4
109.3

balance-sheet.row.account-payables

501.879585.579.4
31
44.7
25.4
28.5
16.1
9.3
7.7
5.8
4.6

balance-sheet.row.short-term-debt

917.63227.4140.3145.7
111.8
58
0
0
0
0
0.2
0
0

balance-sheet.row.tax-payables

38.5816.914.59.9
7.3
3.3
1.2
4
6.3
6.8
6.3
3.6
5.7

balance-sheet.row.long-term-debt-total

711.6284.14782
34.8
0
0
0
0
0
0
0
0

Deferred Revenue Non Current

163.6242.345.645.3
49.7
52.6
16.1
15.9
16.5
15.3
15.5
12.8
0

balance-sheet.row.deferred-tax-liabilities-non-current

8.98---
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

4.090.90.70.4
9.5
5.5
142.7
103.9
49
42.6
6.5
22.2
26.5

balance-sheet.row.total-non-current-liabilities

1573.46130.794.6129.7
87.6
56.2
16.3
15.9
16.5
15.3
15.5
12.8
12.7

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

0.250.100.1
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-liab

3293.52539.2396.9423.8
320.2
292.3
184.4
148.3
81.5
67.2
54.4
40.8
43.9

balance-sheet.row.preferred-stock

0000
0
0
0
0
0
0
0
0
0

balance-sheet.row.common-stock

637.07159.3158.8140
140
141.2
141.8
141.9
140
56
56
35
35

balance-sheet.row.retained-earnings

-202.4153.5180.9215.8
203.3
191.9
191.8
197.5
173.1
79.9
74.5
57.7
18.9

balance-sheet.row.accumulated-other-comprehensive-income-loss

1403.6947.652.149.6
47
0
0
0
0
0
0
0
0

balance-sheet.row.other-total-stockholders-equity

1276.51668.1651.6171.2
175.3
220.7
218.5
213
206.1
20.9
12.6
15.8
11.5

balance-sheet.row.total-stockholders-equity

3114.86928.51043.4576.6
565.6
553.9
552
552.4
519.2
156.9
143.1
108.6
65.4

balance-sheet.row.total-liabilities-and-stockholders-equity

6650.841494.81446.81005.8
895.9
854.5
736.5
700.7
600.7
224.1
197.5
149.4
109.3

balance-sheet.row.minority-interest

242.4627.26.55.4
10.2
8.3
0
0
0
0
0
0
0

balance-sheet.row.total-equity

3357.32955.61049.8582
575.7
562.2
552
552.4
519.2
156.9
143.1
108.6
65.4

balance-sheet.row.total-liabilities-and-total-equity

6650.84---
-
-
-
-
-
-
-
-
-

Total Investments

647.74170.710069.9
39.9
14.5
18.2
16.2
4.9
0
0
0
0

balance-sheet.row.total-debt

1629.25311.5187.3227.7
146.6
58
0
0
0
0
0.2
0
0

balance-sheet.row.net-debt

565.5572.6-206.291.7
52.9
-27.9
-408.1
-414.9
-393.4
-75.7
-71.2
-53.4
-38.7

Cash Flow Statement

The financial landscape of Fujian Cosunter Pharmaceutical Co., Ltd. has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of -0.642. The company recently extended its share capital by issuing 0, marking a difference of 0.309 compared to the previous year. Interestingly, a portion of the company's stock, specifically 0, was bought back by the company itself. This action resulted in a change of 0.000 from the previous year. Meanwhile, the company's account payables are currently standing at 51.5 in the reporting currency. The company's investing activities resulted in net cash usage, amounting to -197205434.450 in the reporting currency. This is a shift of 0.131 from the previous year. In the same period, the company recorded 58.6, -35, and -248.35, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of 0.000, with a year over year difference of 0.000. Furthermore, the company allocated -10.35 for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as 421.24, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.

common:word.in-mln

USD
Growth
TTM202220212020201920182017201620152014201320122011

cash-flows.row.net-income

-251.74-140.6-34.216.5
12.6
16.7
33.6
66.4
103.5
83.8
57.3
43.2
0

cash-flows.row.depreciation-and-amortization

52.1358.65237.3
34.6
22.6
15.2
11.7
8.6
6.9
5.9
4.7
0

cash-flows.row.deferred-income-tax

0-29.4-19.5-7.1
-7.5
0
0
0
0
0
0
0
0

cash-flows.row.stock-based-compensation

029.419.57.1
7.5
0
0
0
0
0
0
0
0

cash-flows.row.change-in-working-capital

020.4-21.9-35.7
-14.3
-33.5
18.7
-9
-3.3
15.6
-0.2
-6.8
0

cash-flows.row.account-receivables

0-11-8.21.9
11.9
0
0
0
0
0
0
0
0

cash-flows.row.inventory

09.3-30.8-20.4
1.8
-0.8
-6.6
-4.8
-4.6
2.8
-5.7
-3.4
0

cash-flows.row.account-payables

051.536.6-10.2
-20.5
0
0
0
0
0
0
0
0

cash-flows.row.other-working-capital

0-29.4-19.5-7.1
-7.5
-32.6
25.3
-4.2
1.3
12.8
5.6
-3.4
0

cash-flows.row.other-non-cash-items

-5.06-58.1-13.6-2.5
1.2
5.1
4
4.7
2.9
0.8
3.2
0.9
0

cash-flows.row.net-cash-provided-by-operating-activities

-204.66000
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

-245.8-196-174.4-54.5
-67.8
-229.3
-35.6
-82.5
-32
-31
-24.6
-26.2
-20

cash-flows.row.acquisitions-net

0.0635026.5
10.5
-89.8
0
-15
-5
0
0
0
20

cash-flows.row.purchases-of-investments

-9.74-1.60-17.6
-24.2
-0.3
-4.7
0
-25
0
0
0
-13

cash-flows.row.sales-maturities-of-investments

9.710.30-26.5
0
229.3
0
20.1
5
0
0
0
13.1

cash-flows.row.other-investing-activites

-9.41-35037
8
-229.3
50
230
-280
0
0
0
-39.9

cash-flows.row.net-cash-used-for-investing-activites

-255.18-197.2-174.4-35
-73.5
-319.4
9.7
152.7
-336.9
-31
-24.6
-26.2
-19.9

cash-flows.row.debt-repayment

-322.61-248.4-192.8-129
-105.6
-38
0
0
0
-0.2
0
0
-28

cash-flows.row.common-stock-issued

0000
33.7
0
0
0
0
0
0
0
0

cash-flows.row.common-stock-repurchased

0000
-33.7
0
0
0
0
0
0
0
0

cash-flows.row.dividends-paid

-14.74-10.4-9.2-8.8
-7.4
-15.2
-35.4
-35
0
-70
-22.8
0
-1

cash-flows.row.other-financing-activites

707.86421.2647.5199.5
160.3
39.5
-2.6
59.9
262.7
-1.4
-0.9
-1
8.3

cash-flows.row.net-cash-used-provided-by-financing-activities

370.52162.5445.661.7
47.3
-13.7
-38
24.9
262.7
-71.6
-23.7
-1
-20.7

cash-flows.row.effect-of-forex-changes-on-cash

-0.31000
0
0
0
0
0
0
0
0
0

cash-flows.row.net-change-in-cash

-89.64-154.4253.442.3
7.8
-322.2
43.2
251.5
37.4
4.4
17.9
14.7
12.6

cash-flows.row.cash-at-end-of-period

1054.12234.8389.2135.7
93.5
85.7
407.8
364.6
113.2
75.7
71.4
53.4
38.7

cash-flows.row.cash-at-beginning-of-period

1143.76389.2135.793.5
85.7
407.8
364.6
113.2
75.7
71.4
53.4
38.7
26.1

cash-flows.row.operating-cash-flow

-204.66-119.7-17.815.6
34
10.9
71.5
73.8
111.6
107
66.2
42
53.2

cash-flows.row.capital-expenditure

-245.8-196-174.4-54.5
-67.8
-229.3
-35.6
-82.5
-32
-31
-24.6
-26.2
-20

cash-flows.row.free-cash-flow

-450.46-315.6-192.2-38.9
-33.8
-218.3
35.9
-8.7
79.7
76
41.6
15.7
33.2

Income Statement Row

Fujian Cosunter Pharmaceutical Co., Ltd.'s revenue saw a change of 0.041% compared with the previous period. The gross profit of 300436.SZ is reported to be 227. The company's operating expenses are 447.53, showing a change of 51.639% from the last year. The expenses for depreciation and amortization are 58.6, which is a 0.127% change from the last accounting period. Operating expenses are reported to be 447.53, which shows a 51.639% year-over-year change. Selling and marketing expenses are 0, which is a 0.000% change compared to the previous year. The EBITDA based on the recent numbers is 0, representing a -2.603% year-over-year growth. The operating income is -160.29, which shows a 2.603% change when compared to the previous year. The change in the net income is 2.652%. The net income for the last year was -127.4.

common:word.in-mln

USD
Growth
TTM202220212020201920182017201620152014201320122011

income-statement-row.row.total-revenue

367.99385.8370.4368.5
414.9
402.4
296.1
312.9
308.9
254.5
178.2
125.8
105

income-statement-row.row.cost-of-revenue

150.16158.8138.3124.7
93.4
66
38.6
40.8
37.6
36.4
26
17.9
15.2

income-statement-row.row.gross-profit

217.83227232.1243.8
321.5
336.4
257.5
272.1
271.3
218.1
152.1
107.9
89.8

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

157.57---
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

40.22---
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

175.62---
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

-3.38-3.1-1.20.2
-0.4
-0.3
-1.8
4.7
7.3
3.1
1.2
3.1
1.5

income-statement-row.row.operating-expenses

442.03447.5295.1230.9
307.5
321.8
229.1
208
161.9
123.8
87.6
60.3
50.6

income-statement-row.row.cost-and-expenses

592.2606.3433.5355.6
400.9
387.7
267.6
248.8
199.5
160.2
113.6
78.1
65.9

income-statement-row.row.interest-income

6.35.641.3
1.8
5.8
12
10.4
6
1
1.1
0.4
0

income-statement-row.row.interest-expense

28.9310.69.18.9
7.5
1.2
12
10.3
0
0
0
0
0.4

income-statement-row.row.selling-and-marketing-expenses

175.62---
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

-3.38-3.1-1.20.2
-0.4
-0.3
-1.8
4.7
7.3
4
2.2
3.2
1.4

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

-3.38-3.1-1.20.2
-0.4
-0.3
-1.8
4.7
7.3
3.1
1.2
3.1
1.5

income-statement-row.row.total-operating-expenses

-3.38-3.1-1.20.2
-0.4
-0.3
-1.8
4.7
7.3
4
2.2
3.2
1.4

income-statement-row.row.interest-expense

28.9310.69.18.9
7.5
1.2
12
10.3
0
0
0
0
0.4

income-statement-row.row.depreciation-and-amortization

33.7758.65237.3
34.6
22.6
15.2
11.7
8.6
6.9
5.9
4.7
0.7

income-statement-row.row.ebitda-caps

-225.28---
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

-259.05-160.3-44.515.2
12.5
12
37
69.8
114.1
94.5
65.1
47.6
38.7

income-statement-row.row.income-before-tax

-262.43-163.4-45.715.3
12.1
11.8
35.2
74.5
121.4
98.5
67.3
50.8
40.1

income-statement-row.row.income-tax-expense

8.36-22.9-11.5-1.2
-0.4
-5
1.6
8.1
17.9
14.8
10
7.6
6.3

income-statement-row.row.net-income

-251.74-127.4-34.914.8
10.7
16.5
33.6
66.4
103.5
83.8
57.3
43.2
33.8

Frequently Asked Question

What is Fujian Cosunter Pharmaceutical Co., Ltd. (300436.SZ) total assets?

Fujian Cosunter Pharmaceutical Co., Ltd. (300436.SZ) total assets is 1494844681.000.

What is enterprise annual revenue?

The annual revenue is 191460742.000.

What is firm profit margin?

Firm profit margin is 0.592.

What is company free cash flow?

The free cash flow is -2.828.

What is enterprise net profit margin?

The net profit margin is -0.684.

What is firm total revenue?

The total revenue is -0.704.

What is Fujian Cosunter Pharmaceutical Co., Ltd. (300436.SZ) net profit (net income)?

The net profit (net income) is -127403884.790.

What is firm total debt?

The total debt is 311546692.000.

What is operating expences number?

The operating expences are 447529267.000.

What is company cash figure?

Enretprise cash is 208751095.000.